logo
US Air Force's F-15E Strike Eagle gets drone-fighting upgrade with 42 guided rockets

US Air Force's F-15E Strike Eagle gets drone-fighting upgrade with 42 guided rockets

Yahoo26-05-2025
The US Air Force is experimenting with a new loadout for the F-15E Strike Eagle fighter jet that integrates low-cost, precision-guided missiles aimed at countering drones and cruise missiles, according to The War Zone. A Strike Eagle from the 96th Test Wing was spotted carrying six seven-tube launchers loaded with 70mm APKWS II rockets, giving it a payload of up to 42 guided munitions.
Combined with the jet's standard air-to-air missile arsenal, the loadout greatly expands Strike Eagle's ability to engage a range of aerial threats, particularly unmanned systems and low-flying cruise missiles.
The new combat loadout is intended for situations where traditional air-to-air missiles—limited in quantity and costing hundreds of thousands of dollars each—may be inadequate or too costly for high-volume engagements.
The Advanced Precision Kill Weapon System II (APKWS II), also known as the AGR-20, was developed in the early 2000s to turn standard Hydra 70 rockets into precision-guided weapons. Built by a team led by aerospace company BAE Systems, along with Northrop Grumman and General Dynamics, the system keeps most of the original rocket parts—like the motor, warhead, and fuze—but adds a guidance unit in the middle, Army Recognition Group reports.
Designed to improve precision and efficiency, APKWS II helps reduce collateral damage and shortens ordnance handling time by 50 percent. Testing first began in 2002, but after uneven performance, the program was revamped and rebranded as APKWS II in 2005.
Early in 2025, BAE Systems rolled out an upgraded version of the APKWS II missile, now featuring an infrared seeker. This addition allows the missile to lock onto a target's heat signature after the initial laser designation, enhancing its ability to engage fast or maneuverable threats such as loitering munitions.
Since its introduction, APKWS II has become a vital weapon for the US military, evolving from a precise air-to-ground rocket into a flexible tool for attacking both air and ground targets. It has been used on many aircraft, including helicopters like the Apache and Viper, and jets like the F-16, A-10, and F/A-18.
Outfitting the F-15E—which offers greater range and payload than the F-16—with APKWS II transforms the jet into a high-endurance missile truck, capable of staying in the air longer and striking more targets in a single mission.
Furthermore, APKWS II has also been adapted for ground use through systems like VAMPIRE, sent to Ukraine, and the Electronic Advanced Ground Launcher System (EAGLS), acquired by the US Navy in 2024 for counter-drone missions in the Middle East.
In 2023, combat videos showed VAMPIRE systems mounted on M1152 Humvees in Ukraine engaging Russian drones and reportedly intercepting a Kh-59 cruise missile over the Black Sea.
Thus, the improved APKWS II has already seen action a few months ago, when in March, the US Central Command released footage of F-16s using the missile to shoot down Houthi drones over Yemen.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scotiabank Raises Comcast (CMCSA) Price Target, Maintains Sector Perform Rating
Scotiabank Raises Comcast (CMCSA) Price Target, Maintains Sector Perform Rating

Yahoo

time9 minutes ago

  • Yahoo

Scotiabank Raises Comcast (CMCSA) Price Target, Maintains Sector Perform Rating

Comcast Corporation (NASDAQ:CMCSA) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. Scotiabank has nudged its price target on Comcast Corporation (NASDAQ:CMCSA) to $45 from $44.50, maintaining a rating on the stock. The adjustment reflects the bank's cautious optimism toward the broader Telecom, Media, and Technology (TMT) space as macroeconomic pressures intensify. A couple watching their favorite show on TV, enjoying the entertainment network service. In a note to clients, Scotiabank analysts described the TMT sector as a 'great place to hide' amid mounting global uncertainties, including slowing economic momentum and the impact of escalating tariff disputes. The firm sees companies like Comcast as relatively well-positioned to weather volatility, offering stability in a shifting landscape. While financial performance across the sector is expected to hold steady, Scotiabank flagged potential softness in key subscriber metrics. The bank pointed to slowing population growth, largely attributed to reduced immigration, as a factor that may weigh on new customer acquisition, particularly in broadband and wireless segments. Still, the firm sees Comcast's diversified portfolio, which spans broadband, content, and theme parks, as a buffer against near-term pressures. The modest target increase reflects both confidence in Comcast's earnings potential and caution over demographic headwinds. While we acknowledge the potential of CMCSA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.

AppLovin (APP) Reaffirmed as Top Pick by Citi Ahead of Q2 Earnings
AppLovin (APP) Reaffirmed as Top Pick by Citi Ahead of Q2 Earnings

Yahoo

time9 minutes ago

  • Yahoo

AppLovin (APP) Reaffirmed as Top Pick by Citi Ahead of Q2 Earnings

Applovin Corporation (NASDAQ:APP) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. Applovin Corporation (NASDAQ:APP) shares jumped on Monday after Citi reiterated the stock as a top pick heading into the company's second-quarter earnings report, scheduled for August 6. The firm reaffirmed its Buy rating and maintained a $600 price target, citing confidence in AppLovin's performance and outlook. In a note to clients, Citi said it expects second-quarter results to come in at the high end of management's guidance ranges. The firm also highlighted strength in AppLovin's software platform and monetization strategy as key drivers of momentum heading into the second half of 2025 and into 2026. Citi's note emphasized that tailwinds from AI-driven ad targeting and growing demand for mobile app optimization tools continue to support revenue acceleration. With solid execution and rising visibility into long-term growth, Applovin Corporation (NASDAQ:APP) remains well-positioned in a competitive digital ecosystem. The company's upcoming earnings report will be closely watched for further signs of momentum, as investors look for confirmation of Citi's bullish stance and any upward revisions to guidance. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.

JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating
JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating

Yahoo

time9 minutes ago

  • Yahoo

JPMorgan Cuts Sarepta (SRPT) PT, Keeps Overweight Rating

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 10, JPMorgan lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $30 to $28 but kept an 'Overweight' rating. JPMorgan highlighted that there is a 'valuation disconnect' and the current stock price does not fully reflect the long-term value of the company's business. A laboratory technician in a white coat holding a microscope and examining a vial of biopharmaceuticals. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has three FDA-approved treatments for Duchenne Muscular Dystrophy (DMD) with amenable mutations. These treatments are known as Exondys 51, Vyondys 53, and Amondys 45. Additionally, JPMorgan analysts noted that the company's gene therapy, Elevidys, has full approval for use in all ambulatory DMD patients. The company's gene therapy Elevidys currently has full approval for all ambulatory DMD patients, according to JPMorgan. However, Elevidys still holds accelerated approval status while Sarepta Therapeutics, Inc. (NASDAQ:SRPT) continues discussions with the FDA. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a medical research and drug development company focused on developing precision genetic medicines for rare diseases. The company has leading positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). While we acknowledge the potential of SRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store